Easton Pharmaceuticals Inc. Announces Experienced CFO Appointment to Management Team

Easton Pharmaceuticals Inc. Announces Experienced CFO Appointment to Management Team
Lee Hendelson to Join Easton Pharmaceuticals, Public Company Experience Invaluable as New CFO
TORONTO, Aug. 30, 2010 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals (EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically delivered therapeutic healthcare products, announced today that Lee Hendelson has agreed to join the company as Chief Financial Officer. An Accountant, CFO and Controller for various companies during the past 35 years, Mr. Hendelson will provide direction for all financial matters for Easton Pharmaceuticals in his capacity as Chief Financial Officer.

"As a public company, we are extremely pleased to have someone with Lee's solid experience as CFO," says John Easton, Easton Pharmaceuticals' Chairman of the Board. "He will help guide us through all the necessary regulatory filings and financial issues, and we will also be able to leverage many of Lee's proven skill-sets to move Easton Pharmaceuticals forward to success."

Mr. Hendelson played an integral part in the financial management of, and preparation and filings of financial statements for various publicly traded companies, and worked closely with various venture capital firms in New York City and Palm Beach, Florida analyzing profitability for portfolio clients. Prior to joining Easton Pharmaceuticals, Mr. Hendelson built a successful accounting firm in the United States, providing specialized accounting services, tax problem resolution, tax preparation for businesses and estates, due diligence, forecasting and pro-forma financial statements for business plans. Mr. Hendelson attended The City University of New York and received his Bachelors of Science in Accounting.

About Easton Pharmaceuticals Inc.

Toronto-based Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically delivered therapeutic healthcare products. The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment of FSAD (Female Sexual Arousal Disorder). VIORRA is a topical, daily-use product classified by the FDA as containing Generally Regarded as Safe substances and ingredients. For more information, visit http://www.eastonpharma.com
Copyright ©2010 Easton Pharmaceuticals Inc. All rights reserved. Easton Pharmaceuticals, Easton Pharma and, the Easton Pharmaceuticals logo, and all other Easton Pharmaceuticals company, product, and services names and slogans are trademarks or registered trademarks of Easton Pharmaceuticals Inc. Other names and marks are the property of their respective owners.

This highest-value, lowest cost press release is a service of So Act Network's Press Club. www.pressclub.biz

CONTACT:  Easton Pharmaceuticals Inc.
          Media relations:
          (416) 619-0291
          (347) 284-0192
          Fax: +1(888) 877-3723
          Media relations:
            [email protected]
          Investor relations:
            [email protected]
          [email protected]
          www.eastonpharma.com


GlobeNewswire News Releases
 

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.